C5a is generated as a result of cleavage of the terminal complement protein C5, during activation of the complement system via the classical, alternative or lectin pathway. The anaphylatoxin C5a itself is short-lived and in serum is cleaved rapidly into the more stable C5a des-Arg.

As a component of the terminal pathway and a potent anaphylatoxin, both C5a and C5a des-Arg perform many functions including mast cell degranulation, chemotaxis and acts as a powerful inflammatory mediator. C5a may also play a role in hemo-incompatibility of biomaterials and in various disease states including myocardial infarction, stroke, kidney injury and infectious diseases.

The MicroVue C5a Enzyme Immunoassay detects both C5a and C5a des-Arg and is intended for investigations into the status and role of terminal complement pathway activation.

**Performance**

- **Sensitivity**
  - LLOQ: 0.050 ng/mL
  - LOD: 0.01 ng/mL

- **Inter assay CV**
  - < 9.5%

- **Intra assay CV**
  - < 3.7%

**Excellent Reproducibility**

Standardized to characterized AAA gold standard

**Ease of use**

- Automatable on standard EIA analyzers
- No precipitation step

**Time to results**

- Total assay time under 2.5 hours
- Hands-on time less than 30 min.

**Features**

- Ready-to-use reagents
- Normal and Low Controls included
- Standards included

**Product information**

- Direct Capture EIA
- 96 well format
- 40 tests/kit (in duplicate)
- For use with experimental samples including human plasma and serum
- Cat. # A021 RUO (U.S. and Canada)
- Cat. #A025 ROW

For Research Use Only. Not for use in Diagnostic Procedures.

To learn more about C5a or other Quidel products visit our website at www.quidel.com or contact our Technical Services at 1.800.524.6318, 1.408.616.4301 or via fax at 1.408.616.4310.